Takagi T - Search Results

1

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.

Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Motzer R, et al. Among authors: takagi t. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.

2

Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.

Kennoki T, Kondo T, Kimata N, Murakami J, Ishimori I, Nakazawa H, Hashimoto Y, Kobayashi H, Iizuka J, Takagi T, Yoshida K, Tanabe K. Kennoki T, et al. Among authors: takagi t. Jpn J Clin Oncol. 2011 May;41(5):647-55. doi: 10.1093/jjco/hyr015. Epub 2011 Mar 2. Jpn J Clin Oncol. 2011. PMID: 21367805

3

Similar functional outcomes after partial nephrectomy for clinical T1b and T1a renal cell carcinoma.

Iizuka J, Kondo T, Hashimoto Y, Kobayashi H, Ikezawa E, Takagi T, Omae K, Tanabe K. Iizuka J, et al. Among authors: takagi t. Int J Urol. 2012 Nov;19(11):980-6. doi: 10.1111/j.1442-2042.2012.03085.x. Epub 2012 Jun 26. Int J Urol. 2012. PMID: 22735049

4

Comparison of survival rates in patients with metastatic renal cell carcinoma according to treatment era including cytokine and targeted therapy.

Takagi T, Kondo T, Kennoki T, Iizuka J, Kobayashi H, Hashimoto Y, Tanabe K. Takagi T, et al. Jpn J Clin Oncol. 2013 Apr;43(4):439-43. doi: 10.1093/jjco/hys234. Epub 2013 Jan 9. Jpn J Clin Oncol. 2013. PMID: 23303839

5

Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.

Kondo T, Takagi T, Kobayashi H, Iizuka J, Nozaki T, Hashimoto Y, Ikezawa E, Yoshida K, Omae K, Tanabe K. Kondo T, et al. Among authors: takagi t. Jpn J Clin Oncol. 2014 Mar;44(3):270-7. doi: 10.1093/jjco/hyt232. Epub 2014 Jan 27. Jpn J Clin Oncol. 2014. PMID: 24474815

6

Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population.

Hashimoto Y, Takagi T, Kondo T, Iizuka J, Kobayashi H, Omae K, Yoshida K, Tanabe K. Hashimoto Y, et al. Among authors: takagi t. Int J Clin Oncol. 2015 Oct;20(5):1035-41. doi: 10.1007/s10147-015-0812-9. Epub 2015 Mar 12. Int J Clin Oncol. 2015. PMID: 25762166

7

Comparison of survival rates in stage 1 renal cell carcinoma between partial nephrectomy and radical nephrectomy patients according to age distribution: a propensity score matching study.

Takagi T, Kondo T, Iizuka J, Omae K, Kobayashi H, Yoshida K, Hashimoto Y, Tanabe K. Takagi T, et al. BJU Int. 2016 Jun;117(6B):E52-9. doi: 10.1111/bju.13200. Epub 2015 Jul 2. BJU Int. 2016. PMID: 26073989

8

Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.

Omae K, Kondo T, Kennoki T, Takagi T, Iizuka J, Kobayashi H, Hashimoto Y, Tanabe K. Omae K, et al. Among authors: takagi t. Int J Clin Oncol. 2016 Feb;21(1):126-32. doi: 10.1007/s10147-015-0871-y. Epub 2015 Jul 11. Int J Clin Oncol. 2016. PMID: 26163345

9

Use of mammalian target of rapamycin inhibitors after failure of tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma undergoing hemodialysis: A single-center experience with four cases.

Omae K, Kondo T, Takagi T, Iizuka J, Kobayashi H, Hashimoto Y, Tanabe K. Omae K, et al. Among authors: takagi t. Hemodial Int. 2016 Jul;20(3):E1-5. doi: 10.1111/hdi.12390. Epub 2016 Feb 2. Hemodial Int. 2016. PMID: 26833674

10

Sarcopenia and the Modified Glasgow Prognostic Score are Significant Predictors of Survival Among Patients with Metastatic Renal Cell Carcinoma Who are Receiving First-Line Sunitinib Treatment.

Ishihara H, Kondo T, Omae K, Takagi T, Iizuka J, Kobayashi H, Tanabe K. Ishihara H, et al. Among authors: takagi t. Target Oncol. 2016 Oct;11(5):605-617. doi: 10.1007/s11523-016-0430-0. Target Oncol. 2016. PMID: 27023922

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,032 results

Search Page